Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

According to a filing with the Securities and Exchange Commission dated October 21, 2025, Generali Asset Management reduced ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously only sold in injector pens, in single-dose vials -- these are easier and ...

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...